Redx Pharma plc New Grant of Options (6793Q)
March 01 2021 - 3:57AM
UK Regulatory
TIDMREDX
RNS Number : 6793Q
Redx Pharma plc
01 March 2021
REDX PHARMA PLC
("Redx" or "the Company" or "Redx Pharma")
New Grant of Options
Alderley Park, 1 March 2021 Redx Pharma (AIM:REDX), the drug
discovery and development company focused on cancer and fibrosis,
announces that further to the announcement made on 27 October 2020,
Dr Jane Robertson assumed her new role as Chief Medical Officer on
1 March 2021.
In addition, the Company announces that on 1 March 2021, options
over 1,500,000 ordinary shares of 1p each in the share capital of
the Company, were granted to Dr Jane Robertson, Chief Medical
Officer, under the All employee Share Option scheme, on the
following basis:
The options were granted at 66p per share, being the closing
price on 26 February 2021.
Name Position Number of Options Vesting Date Total Options
Granted Held Following
the Grant
Jane Robertson Chief Medical
(PDMR) Officer 100,000 1 March 2022
100,000 1 March 2023
100,000 1 March 2024
1 March 2024
(subject to
performance
1,200,000 conditions) 1,500,000
Following the grant referred to above, the Company will have
granted options over a total of 31,898,764 Ordinary Shares
representing 11.6 per cent. of the share capital in issue. The
number of options that may be awarded under the Scheme, and all
prior share incentive plans, remains limited such that the
aggregate number of Ordinary Shares of 1p each under option will be
less than 15 per cent. of the total issued share capital of the
Company.
1. Details of the person discharging managerial responsibilities/person
closely associated
a) Name Jane Robertson
-------------------------------- -------------------------------------
2. Reason for the notification
-----------------------------------------------------------------------
a) Position/status Chief Medical Officer
-------------------------------- -------------------------------------
b) Initial notification/Amendment Initial Notification
-------------------------------- -------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------
a) Name Redx Pharma Plc
-------------------------------- -------------------------------------
b) LEI 213800HMS4EBXO589Y37
-------------------------------- -------------------------------------
4. Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
-----------------------------------------------------------------------
a) Description of the financial Options over Ordinary Shares of 1p
instrument each
-------------------------------- -------------------------------------
b) Identification code ISIN: GB00BSNB6S51
-------------------------------- -------------------------------------
c) Nature of the transactions Grant of options under the Redx All
Employee Share Option Scheme
-------------------------------- -------------------------------------
d) Price(s) and volume(s) Price: 66p pence per share
Volume: 1,500,000 shares
-------------------------------- -------------------------------------
e) Aggregated information As for d) above
- Aggregated volume
- Price
-------------------------------- -------------------------------------
f) Date of the transactions 1 March 2021
-------------------------------- -------------------------------------
f) Place of the transactions Off-market
-------------------------------- -------------------------------------
For further information, please contact:
Redx Pharma Plc T: +44 1625 469
918
Iain Ross, Chairman
Lisa Anson, Chief Executive
James Mead, Chief Financial Officer
SPARK Advisory Partners (Nominated Adviser) T: +44 203 368
3550
Matt Davis/Adam Dawes
WG Partners LLP (Broker) T: +44 20 3705
9330
Claes Spång/Chris Lee/David Wilson
FTI Consulting T: +44 20 3727
1000
Simon Conway/Ciara Martin
About Redx Pharma Plc
Redx Pharma (AIM:REDX) is focused on the discovery and
development of novel targeted medicines for the treatment of cancer
and fibrotic disease, aiming to progress them to clinical proof of
concept. Redx's lead oncology asset, RXC004, is currently in a
phase 1 study in patients with advanced malignancies with top line
data expected in H1 2021 and the Company's selective ROCK2
inhibitor, RXC007, is expected to enter a phase 1 clinical study in
H1 2021.
The Company's core capability of converting medicinal chemistry
insights into differentiated and commercially attractive small
molecule drug candidates against clinically validated targets has
been recognized by others. Over the last three years the company
has completed four major preclinical stage deals with AstraZeneca,
Jazz Pharmaceuticals and Loxo Oncology (now Eli Lilly).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHKFLBBFXLZBBQ
(END) Dow Jones Newswires
March 01, 2021 04:57 ET (09:57 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Apr 2024 to May 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From May 2023 to May 2024